[go: up one dir, main page]

LT2172212T - Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus - Google Patents

Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus

Info

Publication number
LT2172212T
LT2172212T LTEP08017921.1T LT08017921T LT2172212T LT 2172212 T LT2172212 T LT 2172212T LT 08017921 T LT08017921 T LT 08017921T LT 2172212 T LT2172212 T LT 2172212T
Authority
LT
Lithuania
Prior art keywords
tumors
against several
immunotherapy against
including neuronal
novel immunotherapy
Prior art date
Application number
LTEP08017921.1T
Other languages
English (en)
Lithuanian (lt)
Inventor
Oliver Schoor
Norbert Hilf
Toni Weinschenk
Claudia Trautwein
Steffen Walter
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of LT2172212T publication Critical patent/LT2172212T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
LTEP08017921.1T 2008-10-01 2008-10-13 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus LT2172212T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers

Publications (1)

Publication Number Publication Date
LT2172212T true LT2172212T (lt) 2016-11-10

Family

ID=40342382

Family Applications (10)

Application Number Title Priority Date Filing Date
LTEP08017921.1T LT2172212T (lt) 2008-10-01 2008-10-13 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179174.4T LT3120868T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179192.6T LT3120869T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179226.2T LT3120870T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179169.4T LT3132801T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP09778749.3T LT2331118T (lt) 2008-10-01 2009-09-28 Su navikais susijusių peptidų ir susijusios preišvėžinės vakcinos, skirtos glioblastomos (gbm) ir kitų vėžinių ligų gydymui, kompozicija
LTEP16179214.8T LT3124043T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija prieš tam tikrus navikus, įskaitant neuronų ir galvos smegenų navikus
LTEP16179241.1T LT3111952T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179163.7T LT3106175T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16165070.0T LT3069728T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija prieš keletą auglių, įskaitant neuroninius ir smegenų auglius

Family Applications After (9)

Application Number Title Priority Date Filing Date
LTEP16179174.4T LT3120868T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179192.6T LT3120869T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179226.2T LT3120870T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179169.4T LT3132801T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP09778749.3T LT2331118T (lt) 2008-10-01 2009-09-28 Su navikais susijusių peptidų ir susijusios preišvėžinės vakcinos, skirtos glioblastomos (gbm) ir kitų vėžinių ligų gydymui, kompozicija
LTEP16179214.8T LT3124043T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija prieš tam tikrus navikus, įskaitant neuronų ir galvos smegenų navikus
LTEP16179241.1T LT3111952T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16179163.7T LT3106175T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija nuo tam tikrų navikų, įskaitant neuronų ir galvos smegenų navikus
LTEP16165070.0T LT3069728T (lt) 2008-10-01 2009-09-28 Nauja imunoterapija prieš keletą auglių, įskaitant neuroninius ir smegenų auglius

Country Status (24)

Country Link
US (19) US8318677B2 (pl)
EP (12) EP2172211B1 (pl)
JP (10) JP5855940B2 (pl)
KR (6) KR102133402B1 (pl)
CN (3) CN102170901B (pl)
AU (2) AU2009300088B2 (pl)
BR (2) BRPI0920791B8 (pl)
CA (9) CA2936870C (pl)
CY (11) CY1116302T1 (pl)
DK (12) DK2172211T3 (pl)
EA (3) EA032437B1 (pl)
ES (12) ES2536465T3 (pl)
HR (12) HRP20160915T1 (pl)
HU (11) HUE031030T2 (pl)
LT (10) LT2172212T (pl)
MX (3) MX2011003540A (pl)
NZ (4) NZ603016A (pl)
PL (12) PL2172211T3 (pl)
PT (12) PT2172211E (pl)
RS (12) RS53782B1 (pl)
SI (12) SI2172211T1 (pl)
TR (2) TR201900852T4 (pl)
UA (3) UA125277C2 (pl)
WO (2) WO2010037514A2 (pl)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435507B2 (en) 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
US20120052080A1 (en) * 2004-09-21 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
EA034800B1 (ru) * 2007-07-27 2020-03-23 Имматикс Байотекнолоджиз Гмбх Пептид, связывающийся с мнс-i, индуцирующий цтл и стимулирующий антиопухолевые иммунные ответы
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
PL2119726T5 (pl) * 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
RS53782B1 (en) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2012075490A2 (en) * 2010-12-03 2012-06-07 Duke University Anti-podoplanin antibodies and methods of use
JP6032853B2 (ja) * 2010-12-14 2016-11-30 イマティクス バイオテクノロジーズ ゲーエムベーハー 前立腺関連抗原分子由来ｈｌａ結合ペプチドおよびその使用方法
US20140154269A1 (en) * 2011-04-26 2014-06-05 The Methodist Hospital Research Institute Targeted nanovectors and their use for treatment of brain tumors
US9889209B2 (en) 2011-09-14 2018-02-13 Northwestern University Nanoconjugates able to cross the blood-brain barrier
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
KR20210048608A (ko) 2012-01-20 2021-05-03 데니스 엠. 브라운 다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
EP3536334B1 (en) 2012-05-16 2021-06-23 Stemline Therapeutics Inc. Cancer stem cell targeted cancer vaccines
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
TWI819228B (zh) * 2013-08-05 2023-10-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
ES3008994T3 (en) 2013-08-05 2025-03-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors, such as lung cancer including nsclc
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
JP6817069B2 (ja) 2014-04-25 2021-01-20 ブルーバード バイオ， インコーポレイテッド 養子細胞療法薬を製造するための改善された方法
SG10201809379UA (en) 2014-04-25 2018-11-29 Bluebird Bio Inc Mnd promoter chimeric antigen receptors
WO2015182668A1 (ja) * 2014-05-28 2015-12-03 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
NZ726989A (en) 2014-06-06 2020-08-28 Bluebird Bio Inc Improved t cell compositions
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
CN106795217B (zh) 2014-07-24 2021-08-06 蓝鸟生物公司 Bcma嵌合抗原受体
AU2014410466B2 (en) * 2014-11-06 2019-09-12 Ose Immunotherapeutics Therapeutic multi-peptides T specific immune therapy for treatment of brain metastasis
HK1245801B (en) 2014-12-12 2020-05-15 2Seventy Bio, Inc. Bcma chimeric antigen receptors
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
LT3626729T (lt) 2014-12-23 2021-10-25 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
KR20240151873A (ko) 2015-03-17 2024-10-18 이매틱스 바이오테크놀로지스 게엠베하 췌장암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
JP6985153B2 (ja) * 2015-05-06 2021-12-22 イマティクス バイオテクノロジーズ ゲーエムベーハー 結腸直腸がん（ｃｒｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチドとそのスキャフォールドとの組み合わせ
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
US11305002B2 (en) 2015-06-09 2022-04-19 The Board Of Regents Of The University Of Oklahoma Compositions and treatments for Haemophilus influenzae
KR20180015269A (ko) 2015-06-24 2018-02-12 이모듈런 테라퓨틱스 리미티드 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MY191654A (en) 2015-07-01 2022-07-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PT3319985T (pt) * 2015-07-06 2021-01-06 Immatics Biotechnologies Gmbh Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IL309003A (en) 2015-08-28 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunothera-peutic treatment of various cancers
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017040885A1 (en) 2015-09-03 2017-03-09 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
CN108289909A (zh) 2015-10-19 2018-07-17 巴尔的摩马里兰大学 用于产生工程改造的人原代血液树突细胞系的方法
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
KR20180107102A (ko) 2015-12-16 2018-10-01 그릿스톤 온콜로지, 인코포레이티드 신생항원 동정, 제조, 및 용도
US10604759B2 (en) 2016-01-15 2020-03-31 City Of Hope Targeting glioblastoma stem cells through the TLX-TET3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
CN105664134B (zh) * 2016-03-13 2019-04-26 浙江药苑生物科技有限公司 一种用于治疗骨癌的药物组合物
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
MY193474A (en) 2016-03-16 2022-10-15 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
JP6989136B2 (ja) * 2016-04-06 2022-01-05 イマティクス バイオテクノロジーズ ゲーエムベーハー Ａｍｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
EP3518948B1 (en) * 2016-10-03 2023-04-12 Ottawa Hospital Research Institute Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic rna viruses
MX2019005277A (es) 2016-11-04 2019-09-27 Bluebird Bio Inc Composiciones de celulas t con car anti-bcma.
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
AU2017379900B2 (en) 2016-12-22 2024-12-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR102427192B1 (ko) 2017-01-06 2022-07-29 주식회사 유틸렉스 항-인간 4-1bb 항체 및 그의 용도
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
US20180248175A1 (en) * 2017-02-28 2018-08-30 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
SG11201910101SA (en) * 2017-05-08 2019-11-28 Gritstone Oncology Inc Alphavirus neoantigen vectors
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
IL274799B2 (en) 2017-11-22 2025-05-01 Gritstone Bio Inc Reducing junction epitope presentation for neoantigens
WO2019118793A2 (en) * 2017-12-14 2019-06-20 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
CN111480345B (zh) 2017-12-14 2022-04-29 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
HRP20230007T1 (hr) * 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
CN113645997B (zh) 2019-03-29 2024-12-17 英特维特国际股份有限公司 在液体组合物中对活的柔膜菌纲细菌的稳定化
CN113939320A (zh) 2019-04-05 2022-01-14 医尔利有限公司 用于合成的生物标志物的改进的方法和组合物
CN114207675A (zh) 2019-05-28 2022-03-18 佩治人工智能公司 用于数字病理学的用于处理图像以针对所处理的图像制备载片的系统和方法
TWI856108B (zh) 2019-05-30 2024-09-21 美商磨石生物公司 經修飾之腺病毒
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
EP4087602A4 (en) * 2020-01-10 2023-11-29 The Brigham & Women's Hospital, Inc. Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
US20230055337A1 (en) * 2020-02-24 2023-02-23 The Regents Of The University Of California Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN111333698B (zh) * 2020-03-18 2021-11-23 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原组合、乳腺癌靶标抗原组合刺激培养的ctl细胞及其应用
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
KR20230006821A (ko) * 2020-03-31 2023-01-11 워킹 피쉬 테라퓨틱스 변형 b 세포 및 이의 사용 방법
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof
AU2021320896A1 (en) 2020-08-06 2023-03-23 Seattle Project Corp. Multiepitope vaccine cassettes
KR102711471B1 (ko) 2020-08-14 2024-09-30 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
US20220062406A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
US20250235517A1 (en) * 2022-03-30 2025-07-24 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IN151589B (pl) 1978-12-22 1983-05-28 Biogen Nv
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
US6193969B1 (en) 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
JP2002513381A (ja) * 1996-07-22 2002-05-08 ザ ロックフェラー ユニバーシティー ＨＴＬＶ―Ｉ感染およびＨＴＬＶ―ＩＩ感染を予防するためのｅｎｖ―糖タンパク質ワクチン
AU6240798A (en) 1997-01-15 1998-08-07 Zymogenetics Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
WO1998036062A1 (en) * 1997-02-13 1998-08-20 Smithkline Beecham Plc Neural cell adhesion molecule splicing variants
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU750358B2 (en) * 1997-12-02 2002-07-18 Medarex, Inc. Cells expressing anti-Fc receptor binding components
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU3762699A (en) * 1998-04-27 1999-11-16 Pacific Northwest Cancer Foundation (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US20030082586A1 (en) * 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
US20030139327A9 (en) * 2000-01-31 2003-07-24 Rosen Craig A. Nucleic acids, proteins, and antibodies
CA2393002A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1294748B1 (en) 2000-03-27 2010-06-30 Technion Research and Development of Foundation, Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2002020036A1 (de) * 2000-09-06 2002-03-14 Mueller Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU2002226030A1 (en) * 2000-12-04 2002-06-18 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1379879A2 (en) * 2000-12-08 2004-01-14 Oxford GlycoSciences (UK) Limited Diagnosis and treatment of alzheimer's disease
WO2002074237A2 (en) * 2001-03-19 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
WO2004067029A1 (fr) * 2002-12-27 2004-08-12 Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd. Procede de preparation d'un vaccin et vaccins antitumoraux
WO2004089300A2 (en) 2003-04-04 2004-10-21 Pharmacyclics, Inc. Sapphyrins and uses thereof
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
WO2005071075A1 (ja) * 2004-01-23 2005-08-04 Green Peptide Co., Ltd. 上皮細胞増殖因子受容体（egfr）由来ペプチド
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20080280317A1 (en) * 2004-08-27 2008-11-13 Northeastern University Comprehensive Characterization Of Complex Proteins At Trace Levels
ES2319286T3 (es) * 2004-10-02 2009-05-06 Immatics Biotechnologies Gmbh Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
US7902143B2 (en) * 2004-12-07 2011-03-08 Toray Industries, Inc. Cancer antigen peptide and the use thereof
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
PT1806359E (pt) 2005-09-05 2010-05-25 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
PL1760089T3 (pl) * 2005-09-05 2010-03-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
US20070099251A1 (en) 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
US9487574B2 (en) * 2006-09-21 2016-11-08 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
EP2084267B1 (en) * 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2679743A1 (en) * 2007-03-06 2008-09-12 Barry G. Arnason Methods and compositions involving polymeric immunoglobulin fusion proteins
EP2280731A1 (en) * 2008-04-09 2011-02-09 Technion Research and Development Foundation, Ltd. Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko) * 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
RS53782B1 (en) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
SG10202001285XA (en) * 2014-05-28 2020-04-29 Nono Inc Chloride salt of tat-nr2b9c
PE20181897A1 (es) 2016-04-21 2018-12-11 Immatics Biotechnologies Gmbh Inmunoterapia contra el melanoma y otros tipos de cancer
US12221465B2 (en) * 2017-09-06 2025-02-11 California Institute Of Technology Signaling and antigen-presenting bifunctional receptors (SABR)

Also Published As

Publication number Publication date
EA201401104A1 (ru) 2015-05-29
HRP20201015T8 (hr) 2022-01-21
PT3120868T (pt) 2020-07-16
US9993540B2 (en) 2018-06-12
CA2739387A1 (en) 2010-04-08
CA2936869A1 (en) 2010-04-08
CA2936920A1 (en) 2010-04-08
EP2331118A1 (en) 2011-06-15
HUE049366T2 (hu) 2020-09-28
DK3111952T3 (en) 2019-01-28
JP2016047825A (ja) 2016-04-07
US20120141517A1 (en) 2012-06-07
PT3111952T (pt) 2019-02-05
ES2788129T3 (es) 2020-10-20
US20160376316A1 (en) 2016-12-29
EP3124043A1 (en) 2017-02-01
HRP20182151T1 (hr) 2019-02-08
PT2172212T (pt) 2016-12-22
JP2014239681A (ja) 2014-12-25
CY1121258T1 (el) 2020-05-29
PT3120870T (pt) 2020-07-01
US20160376315A1 (en) 2016-12-29
DK2341927T3 (en) 2016-08-15
AU2009300087B2 (en) 2014-09-04
KR102392070B1 (ko) 2022-04-29
JP2016145210A (ja) 2016-08-12
LT3124043T (lt) 2020-07-10
US20160376312A1 (en) 2016-12-29
PL3106175T3 (pl) 2020-08-24
EP2172212A2 (en) 2010-04-07
JP6297632B2 (ja) 2018-03-20
CY1119744T1 (el) 2018-06-27
US20130004456A1 (en) 2013-01-03
CA2936920C (en) 2019-12-03
SI3124043T1 (sl) 2020-07-31
PL2341927T3 (pl) 2016-11-30
CY1123113T1 (el) 2021-10-29
JP6150859B2 (ja) 2017-06-21
US20170326217A1 (en) 2017-11-16
US10046037B2 (en) 2018-08-14
ES2708654T3 (es) 2019-04-10
EP3106175A1 (en) 2016-12-21
EP3120869B1 (en) 2020-07-22
CY1118702T1 (el) 2017-07-12
EP3120870A1 (en) 2017-01-25
US10919931B2 (en) 2021-02-16
PT2172211E (pt) 2015-03-09
US20210253637A1 (en) 2021-08-19
US20210347822A1 (en) 2021-11-11
KR20200085381A (ko) 2020-07-14
MX2011003540A (es) 2011-06-20
US10941181B2 (en) 2021-03-09
DK2331118T5 (en) 2017-06-19
CN106986919A (zh) 2017-07-28
PL3120868T3 (pl) 2020-08-24
PL3111952T3 (pl) 2019-04-30
EP3120870B1 (en) 2020-04-01
HUE051030T2 (hu) 2021-01-28
PT3132801T (pt) 2020-02-04
ES2710608T3 (es) 2019-04-26
LT3120870T (lt) 2020-08-10
SI3120870T1 (sl) 2020-08-31
US10047123B2 (en) 2018-08-14
CY1123089T1 (el) 2021-10-29
DK3120868T3 (da) 2020-06-22
KR20160103558A (ko) 2016-09-01
US10906936B2 (en) 2021-02-02
HUE047365T2 (hu) 2020-04-28
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
EP2172211A1 (en) 2010-04-07
HRP20161504T1 (hr) 2016-12-30
HRP20201025T8 (hr) 2022-01-07
LT3120868T (lt) 2020-08-10
US8119139B2 (en) 2012-02-21
EP3120868A1 (en) 2017-01-25
AU2009300088B2 (en) 2014-09-04
CA2936868C (en) 2019-10-22
EP3132801B1 (en) 2019-10-30
CN102170901B (zh) 2015-01-07
HUE030296T2 (en) 2017-04-28
JP5753783B2 (ja) 2015-07-22
EA201100586A1 (ru) 2011-10-31
EA023378B1 (ru) 2016-05-31
EA201100587A1 (ru) 2011-10-31
HRP20200722T1 (hr) 2020-10-16
ES2802227T3 (es) 2021-01-18
AU2009300087A1 (en) 2010-04-08
CY1122913T1 (el) 2021-10-29
DK3120869T3 (da) 2020-08-10
JP6294913B2 (ja) 2018-03-14
US20160376314A1 (en) 2016-12-29
HUE050428T2 (hu) 2020-12-28
PT3106175T (pt) 2020-07-01
LT3069728T (lt) 2019-02-11
CY1122677T1 (el) 2021-03-12
HRP20201025T1 (hr) 2020-12-25
EP3124043B1 (en) 2020-04-29
US10100085B2 (en) 2018-10-16
US20110002963A1 (en) 2011-01-06
JP5855940B2 (ja) 2016-02-09
CY1121098T1 (el) 2019-12-11
JP2012504563A (ja) 2012-02-23
HUE031030T2 (en) 2017-06-28
PL3132801T3 (pl) 2020-06-15
RS55543B1 (sr) 2017-05-31
JP5883476B2 (ja) 2016-03-15
RS55531B1 (sr) 2017-05-31
RS60386B1 (sr) 2020-07-31
KR102133402B1 (ko) 2020-07-14
JP2017018102A (ja) 2017-01-26
WO2010037514A2 (en) 2010-04-08
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
CA2936887C (en) 2019-11-12
HRP20201228T1 (hr) 2021-02-05
US20160376313A1 (en) 2016-12-29
CA2936887A1 (en) 2010-04-08
KR101883426B1 (ko) 2018-07-31
SI3120869T1 (sl) 2020-10-30
RS60385B1 (sr) 2020-07-31
KR20110074894A (ko) 2011-07-04
RS53782B1 (en) 2015-06-30
LT3106175T (lt) 2020-08-10
CA2739384A1 (en) 2010-04-08
TR201900809T4 (tr) 2019-02-21
PT2331118T (pt) 2017-02-06
US20150125478A1 (en) 2015-05-07
NZ624533A (en) 2015-09-25
DK2172211T3 (en) 2015-02-16
SI3132801T1 (sl) 2020-03-31
KR20110082155A (ko) 2011-07-18
HK1161106A1 (en) 2012-08-24
US11136352B2 (en) 2021-10-05
ES2804723T3 (es) 2021-02-09
CY1123098T1 (el) 2021-10-29
CA2936868A1 (en) 2010-04-08
US20160376317A1 (en) 2016-12-29
PL2331118T3 (pl) 2017-05-31
US12221493B2 (en) 2025-02-11
HRP20200988T1 (hr) 2020-10-16
BRPI0920759A2 (pt) 2016-03-08
HUE049364T2 (hu) 2020-09-28
SI3111952T1 (sl) 2019-01-31
PT2341927T (pt) 2016-08-02
KR101687840B1 (ko) 2016-12-19
ES2788129T8 (es) 2020-11-04
CA2936870C (en) 2019-11-26
JP6294914B2 (ja) 2018-03-14
CN102170900A (zh) 2011-08-31
KR20220058655A (ko) 2022-05-09
DK3124043T3 (da) 2020-05-04
JP2017023136A (ja) 2017-02-02
CA2936982C (en) 2019-12-03
CA2739387C (en) 2019-10-29
ES2612466T3 (es) 2017-05-17
US12234298B2 (en) 2025-02-25
EP2172211B1 (en) 2014-12-03
EP2172212B1 (en) 2016-10-05
CA2936982A1 (en) 2010-04-08
EA032437B1 (ru) 2019-05-31
EP3111952B1 (en) 2018-10-31
UA110599C2 (uk) 2016-01-25
CA2936924C (en) 2019-07-16
JP2012504393A (ja) 2012-02-23
NZ591855A (en) 2012-11-30
CA2936924A1 (en) 2010-04-08
US20190010190A1 (en) 2019-01-10
ES2802226T3 (es) 2021-01-18
MX338294B (es) 2016-04-11
JP2017000148A (ja) 2017-01-05
DK3106175T3 (da) 2020-06-22
US20160355550A1 (en) 2016-12-08
NZ603016A (en) 2014-05-30
US20130309193A1 (en) 2013-11-21
CY1116302T1 (el) 2017-02-08
US20210238227A1 (en) 2021-08-05
ES2536465T3 (es) 2015-05-25
JP2017029135A (ja) 2017-02-09
JP6214066B2 (ja) 2017-10-18
AU2009300088A1 (en) 2010-04-08
HRP20170115T1 (hr) 2017-03-24
EP3106175B1 (en) 2020-04-01
EP2331118B1 (en) 2016-10-26
PL3124043T3 (pl) 2020-07-27
BRPI0920791B8 (pt) 2022-02-15
CA2739384C (en) 2017-05-02
PT3124043T (pt) 2020-05-12
MX2011003539A (es) 2011-06-20
DK2331118T3 (da) 2017-01-09
CN102170900B (zh) 2016-10-26
WO2010037513A1 (en) 2010-04-08
HRP20150223T8 (hr) 2015-07-03
CA2936870A1 (en) 2010-04-08
EP3069728A1 (en) 2016-09-21
CN102170901A (zh) 2011-08-31
BRPI0920791B1 (pt) 2022-01-18
EP3069728B1 (en) 2018-11-14
RS55043B1 (sr) 2016-12-30
RS60338B1 (sr) 2020-07-31
BRPI0920791A2 (pt) 2019-12-10
ES2607460T3 (es) 2017-03-31
SI3106175T1 (sl) 2020-08-31
HUE049367T2 (hu) 2020-09-28
KR101756488B1 (ko) 2017-07-11
HUE029360T2 (en) 2017-02-28
EP3120868B1 (en) 2020-04-08
EP2172212A3 (en) 2010-04-14
DK3069728T3 (en) 2019-02-25
LT3111952T (lt) 2018-12-27
DK2172212T3 (da) 2016-12-19
EP3132801A1 (en) 2017-02-22
RS58229B1 (sr) 2019-03-29
US8895514B2 (en) 2014-11-25
US20100158931A1 (en) 2010-06-24
US10227381B2 (en) 2019-03-12
EP2341927A2 (en) 2011-07-13
HRP20160915T1 (hr) 2016-10-07
WO2010037514A3 (en) 2010-06-03
PL3120870T3 (pl) 2020-07-27
EP3111952A1 (en) 2017-01-04
TR201900852T4 (tr) 2019-02-21
HRP20201015T1 (hr) 2020-10-16
KR20180088494A (ko) 2018-08-03
HUE042115T2 (hu) 2019-06-28
NZ591882A (en) 2012-12-21
US20210261614A1 (en) 2021-08-26
PL2172212T3 (pl) 2017-04-28
PT3069728T (pt) 2019-02-13
US10047124B2 (en) 2018-08-14
DK3132801T3 (da) 2020-02-10
DK3120870T3 (da) 2020-06-22
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30
US8318677B2 (en) 2012-11-27
EP2341927B1 (en) 2016-05-04
HK1159526A1 (zh) 2012-08-03
EA023013B1 (ru) 2016-04-29
RS58443B1 (sr) 2019-04-30
ES2819244T3 (es) 2021-04-15
SI2172211T1 (sl) 2015-03-31
SI3120868T1 (sl) 2020-08-31
SI2172212T1 (sl) 2016-12-30
RS60381B1 (sr) 2020-07-31
PL2172211T3 (pl) 2015-05-29
US8653035B2 (en) 2014-02-18
HUE041446T2 (hu) 2019-05-28
HRP20190202T1 (hr) 2019-03-22
JP2017018101A (ja) 2017-01-26
US11208434B2 (en) 2021-12-28
CA2936869C (en) 2019-08-06
HRP20200110T1 (hr) 2020-05-15
LT3120869T (lt) 2020-11-10
JP6367266B2 (ja) 2018-08-01
CY1123526T1 (el) 2022-03-24
UA103202C2 (ru) 2013-09-25
US8961985B2 (en) 2015-02-24
ES2770090T3 (es) 2020-06-30
PT3120869T (pt) 2020-09-22
LT2331118T (lt) 2016-12-27
EP3120869A1 (en) 2017-01-25
LT3132801T (lt) 2020-02-10
SI2331118T1 (sl) 2017-01-31
HRP20150223T1 (hr) 2015-06-05
SI3069728T1 (sl) 2019-03-29
ES2584245T3 (es) 2016-09-26

Similar Documents

Publication Publication Date Title
HRP20190202T1 (hr) Nova imunoterapija protiv nekoliko tumora uključujući tumore živčanih stanica i tumore mozga
DK2183361T3 (en) Novel immunotherapy against brain tumors
PL2308885T3 (pl) Nowe związki i sposoby leczenia
GB0819280D0 (en) Imgaing and radiotherapy methods
PL2105501T3 (pl) Innowacyjna immunoterapia przeciwko nowotworom neuronów i mózgu